Back to top
more

Anixa Biosciences (ANIX)

(Delayed Data from NSDQ)

$3.10 USD

3.10
53,923

-0.05 (-1.59%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.08 -0.02 (-0.65%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

Zacks Equity Research

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.

Zacks Equity Research

ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

Zacks Equity Research

What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy

by Zacks Equity Research

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Zacks Equity Research

Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up

by Zacks Equity Research

Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States.

Zacks Equity Research

SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.

Zacks Equity Research

BEAM Down Despite Positive Initial Data From Genetic Disorder Study

by Zacks Equity Research

Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.

Zacks Equity Research

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks Equity Research

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

by Zacks Equity Research

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Zacks Equity Research

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.

Zacks Equity Research

Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised

by Zacks Equity Research

Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.

Zacks Equity Research

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Zacks Equity Research

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Zacks Equity Research

Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss

by Zacks Equity Research

Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.

Zacks Equity Research

Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.

Zacks Equity Research

Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel Revenues

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter. Its shares are trading up in response to the results.

Zacks Equity Research

Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues

by Zacks Equity Research

Acadia (ACAD) reports encouraging second-quarter results as both earnings and revenues beat estimates, driven by higher Nuplazid and Daybue sales.

Zacks Equity Research

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Zacks Equity Research

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected Q2 results, beating both earnings and revenue estimates, primarily driven by strong sales of companion animal products. Management raises the 2024 outlook.

Zacks Equity Research

Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.